A randomized, double-blind, placebo-controlled trial of Abaloparatide men with osteoporosis at high risk for fracture

Trial Profile

A randomized, double-blind, placebo-controlled trial of Abaloparatide men with osteoporosis at high risk for fracture

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Mar 2018

At a glance

  • Drugs Abaloparatide (Primary)
  • Indications Osteoporosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ATOM
  • Sponsors Radius Health Inc.
  • Most Recent Events

    • 30 Mar 2018 Status changed from planning to recruiting, according to a Radius Health media release.
    • 21 Nov 2017 New trial record
    • 02 Nov 2017 According to Radius media release,the compnay expect to initiate this trial in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top